{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:15:02Z","timestamp":1778681702397,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PharmaEssentia Japan KK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Polycythemia vera (PV) is a myeloproliferative neoplasm that is treated according to the patient\u2019s thrombosis risk, including cytoreductive therapies for those at high-risk for thrombosis. Ropeginterferon alfa-2b, a mono-pegylated interferon \u03b1-2b, is a new cytoreductive therapy for PV. This expert consensus study, conducted before ropeginterferon alfa-2b recommendations were added to the Japanese guidelines, used a four-phase Delphi method to survey 18 Japanese hematology experts and develop suggestions for ropeginterferon alfa-2b use in Japan. Several scenarios where ropeginterferon alfa-2b treatment is considered appropriate for patients with PV were identified, including: 1) low-risk patients requiring cytoreductive therapy (excluding low-risk patients requiring cytoreductive therapy due to splenomegaly); 2) patients intolerant or resistant to hydroxyurea treatment; 3) high-risk patients aged\u2009\u2264\u200970\u00a0years, even if hematocrit\u2009&lt;\u200945% is achieved and maintained under hydroxyurea treatment; and 4) patients who wish to conceive or who are pregnant and require cytoreductive therapy. This is the first expert consensus study using the Delphi method to examine cytoreductive therapy for Japanese patients with PV and contributes to the appropriate selection of patients for ropeginterferon alfa-2b in clinical practice.<\/jats:p>","DOI":"10.1007\/s12185-025-04140-8","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:32:15Z","timestamp":1772638335000},"page":"664-677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consensus on the use of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a modified Delphi survey"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2555-8188","authenticated-orcid":false,"given":"Kazuya","family":"Shimoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuto","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Dohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riki","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"4140_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"4140_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3390\/genes13040637","volume":"13","author":"M Regimbeau","year":"2022","unstructured":"Regimbeau M, Mary R, Hermetet F, Girodon F. Genetic background of polycythemia vera. Genes (Basel). 2022;13:637.","journal-title":"Genes (Basel)"},{"key":"4140_CR3","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007;21:1960\u20133.","journal-title":"Leukemia"},{"key":"4140_CR4","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2008.113","volume":"22","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22:1299\u2013307.","journal-title":"Leukemia"},{"key":"4140_CR5","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26008","volume":"95","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:1599\u2013613.","journal-title":"Am J Hematol"},{"key":"4140_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12185-024-03865-2","volume":"121","author":"N Takahashi","year":"2025","unstructured":"Takahashi N, Takenaka K, Iriyama N, Kirito K, Kawaguchi T, Kimura S, et al. JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2025;121:5\u201338.","journal-title":"Int J Hematol"},{"key":"4140_CR7","unstructured":"United States Food & Drug Administration. FDA news release: FDA approves treatment for rare blood disease.\u00a0https:\/\/www.prnewswire.com\/news-releases\/fda-approves-treatment-for-rare-blood-disease-301423378.html. Accessed 3 June 2025."},{"key":"4140_CR8","unstructured":"European Medicines Agency. Besremi (ropeginterferon alfa-2b). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/besremi. Accessed 3 June 2025."},{"key":"4140_CR9","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, et al. Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126:1762\u20139.","journal-title":"Blood"},{"key":"4140_CR10","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196\u2013208.","journal-title":"Lancet Haematol"},{"key":"4140_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12185-022-03341-9","volume":"116","author":"Y Edahiro","year":"2022","unstructured":"Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, et al. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol. 2022;116:215\u201327.","journal-title":"Int J Hematol"},{"key":"4140_CR12","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9:e301\u201311.","journal-title":"Lancet Haematol"},{"key":"4140_CR13","doi-asserted-by":"publisher","first-page":"e1004326","DOI":"10.1371\/journal.pmed.1004326","volume":"21","author":"WT Gattrell","year":"2024","unstructured":"Gattrell WT, Logullo P, van Zuuren EJ, Price A, Hughes EL, Blazey P, et al. ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLoS Med. 2024;21:e1004326.","journal-title":"PLoS Med"},{"key":"4140_CR14","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","volume":"37","author":"H Gisslinger","year":"2023","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia. 2023;37:2129\u201332.","journal-title":"Leukemia"},{"key":"4140_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s44276-024-00076-4","volume":"2","author":"K Kirito","year":"2024","unstructured":"Kirito K, Qin A, Suo S, Fu R, Wu D, Sato T, et al. Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia. BJC Rep. 2024;2:51.","journal-title":"BJC Rep"},{"key":"4140_CR16","doi-asserted-by":"publisher","first-page":"EVIDoa2200335","DOI":"10.1056\/EVIDoa2200335","volume":"2","author":"T Barbui","year":"2023","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Carobbio A, Ghirardi A, Carioli G, et al. Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera. NEJM Evid. 2023;2:EVIDoa2200335.","journal-title":"NEJM Evid"},{"key":"4140_CR17","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood.2023020232","volume":"143","author":"AT Gerds","year":"2024","unstructured":"Gerds AT, Mesa R, Burke JM, Grunwald MR, Stein BL, Squier P, et al. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL. Blood. 2024;143:1646\u201355.","journal-title":"Blood"},{"key":"4140_CR18","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","volume":"119","author":"A Alvarez-Larr\u00e1n","year":"2012","unstructured":"Alvarez-Larr\u00e1n A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hern\u00e1ndez-Boluda JC, Ferrer-Mar\u00edn F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119:1363\u20139.","journal-title":"Blood"},{"key":"4140_CR19","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","volume":"148","author":"G Barosi","year":"2010","unstructured":"Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148:961\u20133.","journal-title":"Br J Haematol"},{"key":"4140_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426\u201335.","journal-title":"N Engl J Med"},{"key":"4140_CR21","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","volume":"7","author":"JJ Kiladjian","year":"2020","unstructured":"Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020;7:e226\u201337.","journal-title":"Lancet Haematol"},{"key":"4140_CR22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-018-0133-0","volume":"8","author":"E Verger","year":"2018","unstructured":"Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, et al. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018;8:94.","journal-title":"Blood Cancer J"},{"key":"4140_CR23","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"JJ Kiladjian","year":"2022","unstructured":"Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Long-term outcomes of polycythemia vera patients treated with ropeginterferon alfa-2b. Leukemia. 2022;36:1408\u201311.","journal-title":"Leukemia"},{"key":"4140_CR24","first-page":"100360","volume":"19","author":"J Okikiolu","year":"2022","unstructured":"Okikiolu J, Woodley C, Cadman-Davies L, O\u2019Sullivan J, Radia D, Garcia NC, et al. Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys). Leuk Res Rep. 2022;19:100360.","journal-title":"Leuk Res Rep"},{"key":"4140_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/hematolrep15010018","volume":"15","author":"SY Bang","year":"2023","unstructured":"Bang SY, Lee SE. A case report of ropeginterferon alfa-2b for polycythemia vera during pregnancy. Hematol Rep. 2023;15:172\u20139.","journal-title":"Hematol Rep"},{"key":"4140_CR26","first-page":"118","volume":"193","author":"I Sanchez","year":"2021","unstructured":"Sanchez I, Woodley C, Durgam G, Curto-Garcia N, Sullivan JO, Robinson SE, et al. A case of polycythaemia vera treated with ropeginterferon-2b during pregnancy. Br J Haematol. 2021;193:118\u20139.","journal-title":"Br J Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04140-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04140-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04140-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:30:17Z","timestamp":1778679017000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04140-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4140"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04140-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kazuya Shimoda has received speaker fees from Novartis Pharma, PharmaEssentia Japan, and GlaxoSmithKline; consulting fees from Sumitomo Pharma, GlaxoSmithKline, and Merck; research funding from AstraZeneca, Meiji Seika Pharma, Incyte Biosciences Japan, and PharmaEssentia Japan; and educational\/academic donations from Chugai Pharmaceutical, Kyowa Kirin, AbbVie, Shionogi, Daiichi Sankyo, Otsuka Pharmaceutical, Eisai, Nippon Kayaku, and Asahi Kasei Medical. Katsuto Takenaka has received speaker fees from PharmaEssentia Japan and Novartis Pharma; writing fees from PharmaEssentia Japan; and research funding from PharmaEssentia Japan. Keita Kirito has received speaker fees from Novartis Pharma, Takeda Pharmaceutical, Sanofi, AbbVie, and PharmaEssentia Japan; and\u00a0writing fees from PharmaEssentia Japan and PharmaEssentia Corporation. Haruna Kitamura, Koji Dohi, and Riki Yoshimoto are employees at LESPEDEZA, a division of EMC K.K., which was funded by the study sponsor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}